Immunotherapy has improved survival rates in NSCLC patients, but identifying those who will respond to treatment remains a challenge. We performed a differential proteomic quantitative analysis based on SWATH–MS technology to analyse the proteome in blood samples collected from patients with advanced NSCLC prior to the start therapy and during the therapy